CN115427445A - 使用抗ccl24抗体的治疗方法 - Google Patents

使用抗ccl24抗体的治疗方法 Download PDF

Info

Publication number
CN115427445A
CN115427445A CN202180029962.8A CN202180029962A CN115427445A CN 115427445 A CN115427445 A CN 115427445A CN 202180029962 A CN202180029962 A CN 202180029962A CN 115427445 A CN115427445 A CN 115427445A
Authority
CN
China
Prior art keywords
ccl24
monoclonal antibody
antibody
administration
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180029962.8A
Other languages
English (en)
Chinese (zh)
Inventor
阿迪·莫尔
阿尔农·阿哈龙
莎伦·哈希穆利
迈克尔·西格尔萨尔托
内塔·巴拉希
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemomab Ltd
Original Assignee
Chemomab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemomab Ltd filed Critical Chemomab Ltd
Publication of CN115427445A publication Critical patent/CN115427445A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CN202180029962.8A 2020-04-22 2021-04-20 使用抗ccl24抗体的治疗方法 Pending CN115427445A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063013793P 2020-04-22 2020-04-22
US63/013,793 2020-04-22
PCT/IL2021/050447 WO2021214759A1 (en) 2020-04-22 2021-04-20 Method of treatment using anti-ccl24 antibody

Publications (1)

Publication Number Publication Date
CN115427445A true CN115427445A (zh) 2022-12-02

Family

ID=75787181

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180029962.8A Pending CN115427445A (zh) 2020-04-22 2021-04-20 使用抗ccl24抗体的治疗方法

Country Status (9)

Country Link
US (1) US20230235037A1 (enExample)
EP (1) EP4139352A1 (enExample)
JP (1) JP2023522907A (enExample)
KR (1) KR20230013037A (enExample)
CN (1) CN115427445A (enExample)
AU (1) AU2021259682A1 (enExample)
CA (1) CA3172627A1 (enExample)
IL (1) IL296579A (enExample)
WO (1) WO2021214759A1 (enExample)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107198773A (zh) * 2017-06-08 2017-09-26 上海药明生物技术有限公司 重组抗pd‑l1全人单克隆抗体的液体制剂
CN109745559A (zh) * 2017-11-01 2019-05-14 三生国健药业（上海）股份有限公司 抗人il-17a的单克隆抗体的液体制剂
CN110300520A (zh) * 2016-10-12 2019-10-01 美国比奥维拉迪维股份有限公司 抗C1s抗体及其使用方法
CN110354073A (zh) * 2018-04-09 2019-10-22 鲁南制药集团股份有限公司 一种免疫抑制剂单克隆抗体的液体制剂
CN110418805A (zh) * 2017-03-08 2019-11-05 彻莫马布有限公司 用于在肝病的治疗中使用的抗ccl24(嗜酸性粒细胞趋化因子2)抗体
CN111051513A (zh) * 2017-07-27 2020-04-21 第一三共株式会社 抗cd147抗体

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6121022A (en) * 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US20040191243A1 (en) * 2002-12-13 2004-09-30 Bei Chen System and method for stabilizing antibodies with histidine
EP1706424B1 (en) * 2004-01-12 2009-07-22 Applied Molecular Evolution, Inc. Fc region variants
US9067989B2 (en) 2009-01-28 2015-06-30 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Eotaxin-2 (CCL24) inhibitors in inflammatory, autoimmune, and cardiovascular disorders
EP2490026A4 (en) * 2009-10-16 2013-08-21 Mochida Pharm Co Ltd MARKER ASSOCIATED WITH NON ALCOHOLIC STÉATOHÉPATITE
BR112012022223B1 (pt) * 2010-03-01 2022-08-09 Cytodyn Inc Formulação de proteína concentrada, uso e método de preparação da mesma
DK3114139T3 (da) 2014-03-04 2022-09-12 Chemomab Ltd Anti eotaxin-2 antistoffer, der genkender supplerende ccr3-bindende chemokiner
CR20170060A (es) * 2014-08-19 2017-04-18 Merck Sharp & Dohme Anticuerpos anti tigit
WO2016040882A1 (en) * 2014-09-13 2016-03-17 Novartis Ag Combination therapies of egfr inhibitors
US20180008707A1 (en) * 2015-02-13 2018-01-11 Sanofi Stable liquid formulation for monoclonal antibodies
JP7155009B2 (ja) * 2016-03-25 2022-10-18 ビステラ， インコーポレイテッド デングウイルスに対する抗体分子の製剤

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110300520A (zh) * 2016-10-12 2019-10-01 美国比奥维拉迪维股份有限公司 抗C1s抗体及其使用方法
CN110418805A (zh) * 2017-03-08 2019-11-05 彻莫马布有限公司 用于在肝病的治疗中使用的抗ccl24(嗜酸性粒细胞趋化因子2)抗体
CN107198773A (zh) * 2017-06-08 2017-09-26 上海药明生物技术有限公司 重组抗pd‑l1全人单克隆抗体的液体制剂
CN111051513A (zh) * 2017-07-27 2020-04-21 第一三共株式会社 抗cd147抗体
CN109745559A (zh) * 2017-11-01 2019-05-14 三生国健药业（上海）股份有限公司 抗人il-17a的单克隆抗体的液体制剂
CN110354073A (zh) * 2018-04-09 2019-10-22 鲁南制药集团股份有限公司 一种免疫抑制剂单克隆抗体的液体制剂

Also Published As

Publication number Publication date
JP2023522907A (ja) 2023-06-01
EP4139352A1 (en) 2023-03-01
IL296579A (en) 2022-11-01
WO2021214759A1 (en) 2021-10-28
KR20230013037A (ko) 2023-01-26
CA3172627A1 (en) 2021-10-28
US20230235037A1 (en) 2023-07-27
AU2021259682A1 (en) 2022-10-20

Similar Documents

Publication Publication Date Title
JP2025170265A (ja) 抗プロ／潜在型ミオスタチン抗体およびその使用方法
CN106103479B (zh) 识别其它ccr3-结合趋化因子的抗嗜酸粒细胞趋化因子-2抗体
WO2020259605A1 (zh) 包含抗cd47/pd-l1双特异性抗体的制剂及其制备方法和用途
TW202302640A (zh) 抗tl1a抗體組合物及肺中之治療方法
TW202346344A (zh) 以tl1a抑制劑及il23抑制劑的組合治療發炎疾病之方法
US12338279B2 (en) Selective and potent inhibitory antibodies of myostatin activation
JP2020532518A (ja) ビメンチン由来のペプチドに特異的に結合する物質を含む皮膚疾患の予防及び治療用組成物
JP2026507534A (ja) 抗ｔｌ１ａ抗体組成物及び皮膚の治療方法
US20190330330A1 (en) Treatment of acute exacerbations of chronic obstructive pulmonary disease by antagonism of the il-20r
CN112839672A (zh) 用于减少脂蛋白a形成以及治疗主动脉瓣硬化和主动脉狭窄的组合物和方法
IL294941A (en) Inhibitors and their uses
CN114423455A (zh) 用于治疗系统性硬化症的药物组合物
CN110418805B (zh) 用于在肝病的治疗中使用的抗ccl24(嗜酸性粒细胞趋化因子2)抗体
RU2832323C1 (ru) Способ лечения с использованием антитела против CCL24
US20230235037A1 (en) Method of treatment using anti-ccl24 antibody
US20250326831A1 (en) Methods for treating disease using psmp antagonists
TW202448933A (zh) 用抗轉化生長因子β３抗體治療ＴＧＦβ相關病症之方法
WO2025253161A1 (en) Methods for treating liver diseases using recombinant fusion proteins comprising interleukin-18-binding protein and antigen binding fragment to serum albumin
CN114746444A (zh) 使用白介素-17(il-17)拮抗剂治疗扁平苔藓的方法
JP2010265213A (ja) 抗オートタキシン・モノクローナル抗体からなる間質性肺疾患治療剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20221202